FDA approval for mTNBC therapy cannot lift Gilead Sciences stock as bearish trend persists

Traders Union
All News
Companies
Gilead Sciences drops 0.97% today

Highlights

Gilead Sciences trades under key moving averages and faces persistent bearish momentum across all major timeframes.
Momentum and trend indicators confirm a weak trend with prevailing downside risks and little evidence of bullish reversal.
Expected range is $121.00–$127.50 next week, with a break below $121 likely opening downside to $114–$115 support.

Sustained downside pressure as multiple moving averages and Ichimoku cap gains

Gilead Sciences (GILD) is trading at $123.94, which is below the MA-20 ($127.63), MA-50 ($130.88), and MA-200 ($129.57), indicating persistent downside pressure across short-, medium-, and long-term trends. The Ichimoku Kijun at $129.28 is above the current price, acting as immediate resistance.

Bearish momentum and fading strength as price consolidates near weekly lows

Momentum indicators on D1 suggest a bearish tone: MACD signals a strong sell and ADX is at a weak 14.30, reinforcing the lack of a clear trend. RSI sits in the low 40s and gives a sell signal, with Stoch RSI and BBP both indicating an overbought condition, suggesting waning bullish momentum and possible reversal risks. CCI is neutral but close to oversold territory, and AO is neutral, showing no strong countertrend force. Over the past week, GILD has edged up $0.18 (0.15%) from the prev_week_close at $123.76, yet remains in the lower part of the weekly range, with volatility at 3.47%. This points to consolidation near recent lows after a recovery from the week’s bottom.

Further declines favored as upside risk remains limited by weak technicals

Looking ahead, the expected price range for the coming week is $121.00 to $127.50, slightly broadening around the current level but normalized for typical volatility and well within the 52-week boundaries of $106.84–$157.29. The calculated probability of an upward move is very low (less than 20%), making further declines more likely based on bearish signals from RSI-W1, ADX-W1, MACD-W1, and MA-50-W1. Baseline scenario: GILD fluctuates sideways between $121 and $127.50. Bullish scenario: a break above $127.50 pushes towards tough resistance near $129.50. Bearish scenario: a drop below $121 could open space towards the next support at $114–$115, though major long-term support is still some distance away.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Gilead Sciences continued to face selling pressure and lacked momentum for a near-term recovery. As market dynamics evolve, investors should remain attentive to any shift in momentum that could establish a new directional trend for GILD.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.